Clinical trials
Liver Cancer (Primary and Metastatic) clinical trials
Below are recruiting liver cancer (primary and metastatic) clinical trials, each written for real people, not researchers. We’re tracking 319 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04747054RecruitingPhase 3
Radiation plus pembrolizumab for newly diagnosed metastatic head and neck cancer
This trial studies whether adding pembrolizumab (an immune system medicine) to radiation can improve outcomes in people newly diagnosed with metastatic head and neck squamous cell cancer. It may help the immune system better recognize and fight the cancer alongside radiation.
AvignonAges 18 years+ - NCT07383857Recruiting
PULSAR radiation plus immunotherapy for advanced abdominal or pelvic tumors
This trial tests a special type of radiation called PULSAR combined with an immunotherapy drug (anti-PD-1) in people whose cancer has spread within the abdomen or pelvis. The goal is to see if this combination can shrink tumors and help people live longer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT03977571Recruiting
Surgery plus cancer drugs for kidney cancer that spread
This trial studies whether removing the kidney tumor with “deferred cytoreductive nephrectomy” (surgery at a later time) works best for people whose metastatic kidney cancer is already present. It compares a standard treatment approach using either immunotherapy (nivolumab/ipilimumab) or a targeted pill plus immunotherapy (TKI/IO), with planned surgery afterward.
Aarhus, Central Region of DenmarkAges 18 years+ - NCT04919382RecruitingPhase 2
Temozolomide plus atezolizumab for advanced small cell lung cancer
This trial studies temozolomide plus atezolizumab in people with metastatic or recurring small cell lung cancer that has already come back or progressed after standard platinum chemotherapy plus immunotherapy. It may help by trying a new combination after prior treatment has stopped working.
Chicago, IllinoisAges 18 years+ - NCT06589804RecruitingPhase 3
Testing cetuximab plus pembrolizumab for advanced head and neck cancer
This trial tests whether adding cetuximab to the standard drug pembrolizumab works better for head and neck cancer that has spread or come back after treatment. It is for people whose cancer did not respond to platinum chemotherapy and whose tumors have a certain immune marker (PD-L1).
Little Rock, ArkansasAges 18 years+ - NCT07015138Recruiting
Comparing two radiation approaches for prostate cancer that has spread a little
This trial is testing whether giving radiation to all spots of cancer that show up on a PSMA PET scan works better than giving radiation only to the main tumor in the prostate. It is for men whose prostate cancer has spread to a few other places (up to 10 spots).
Beijing, Beijing MunicipalityAges 18–85 - NCT05181033RecruitingPhase 2
Lenvatinib plus letrozole versus fulvestrant for metastatic breast cancer
This Phase 2 study compares a combination medicine (lenvatinib plus letrozole) against fulvestrant to treat metastatic estrogen-receptor positive, HER2-negative breast cancer after the cancer has grown despite hormone therapy plus a CDK4/6 inhibitor. It may help by finding a more effective treatment option after your first lines have stopped working.
SingaporeAges 18–99 - NCT06577987RecruitingPhase 1
Study of CID-078 for advanced solid tumors
This trial tests an experimental drug called CID-078 for people with advanced solid tumors that have stopped responding to other treatments. It aims to find the right dose and see if the drug can shrink tumors.
Sarasota, FloridaAges 12 years+ - NCT06954480RecruitingPhase 2
Two drugs vs one for PDL1-negative breast cancer
This trial tests a new combination of two drugs (datopotamab deruxtecan plus durvalumab) against one drug alone (datopotamab deruxtecan) for people with PDL1-negative, triple-negative breast cancer that has spread. The goal is to see if the combination works better.
LondonAges 18 years+ - NCT07344220Enrolling by invitationPhase 2
Maintenance therapy study for stable metastatic pancreatic cancer
This trial tests a new drug, DZ-002, as maintenance therapy for people with metastatic pancreatic cancer whose disease has not worsened after at least 4 months of first-line chemotherapy. The goal is to help keep the cancer under control with fewer side effects.
Newport Beach, CaliforniaAges 18 years+ - NCT05203913RecruitingPhase 2
Bladder cancer trial adds chemo, immunotherapy, and radiation after surgery
This Phase 2 study tests whether adding chemotherapy and immunotherapy along with targeted pelvic radiation after bladder tumor surgery can reduce bladder cancer returning or spreading. It focuses on people with non-metastatic, muscle-invasive urothelial bladder cancer.
RomaAges 18 years+ - NCT05106296RecruitingPhase 1
Chemo-immunotherapy with ibrutinib and indoximod for pediatric brain tumors
This Phase 1 study tests a combination treatment (ibrutinib plus indoximod along with chemotherapy) for children with brain tumors that have come back or are hard to treat. It may help shrink active tumor or control the disease when standard treatments can’t cure it.
Augusta, GeorgiaAges 3–25 - NCT05985655RecruitingPhase 1/Phase 2
Study of GTAEXS617 for advanced solid tumors
This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06650332RecruitingPhase 1/Phase 2
Cadonilimab combo for first-line HER2-positive gastric cancer
This trial tests a new combination treatment (cadonilimab plus chemotherapy) as the first therapy for people with advanced gastric or gastroesophageal junction cancer that has a certain amount of HER2 protein. It aims to see if this combination can shrink tumors and help people live longer.
Hangzhou, ZhejiangAges 18–75 - NCT06903312RecruitingPhase 4
Removing the main kidney tumor during immunotherapy for advanced kidney cancer
This trial tests whether removing or burning (ablating) the main kidney tumor helps people with advanced kidney cancer who are already doing well on immunotherapy. Researchers want to see if combining local treatment with ongoing immunotherapy can improve outcomes.
RomaAges 18 years+ - NCT05655949RecruitingPhase 2
Y-90 radiation plus immunotherapy and chemo for bile duct cancer
This trial studies whether combining Y-90 liver radiation with an immunotherapy drug (durvalumab) and chemo (gemcitabine and cisplatin) can better control locally advanced or metastatic intrahepatic cholangiocarcinoma (bile duct cancer in the liver). It may help shrink tumors and slow disease growth, depending on how well the treatment works for your cancer type and overall health.
Boston, MassachusettsAges 18 years+ - NCT05040360RecruitingPhase 2
Chemotherapy after surgery for high-risk pancreatic NET tumors
This Phase 2 trial studies whether giving chemotherapy after surgery can lower cancer recurrence risk in people with high-risk pancreatic neuroendocrine tumors (NETs). It may help you by testing an added treatment after the tumor has been removed.
Anchorage, AlaskaAges 18 years+ - NCT06241846RecruitingPhase 2
Study of YL201 for advanced prostate cancer that has spread and stopped responding to hormone therapy
This trial tests a new drug, YL201, in men with advanced prostate cancer that has spread and is no longer controlled by standard hormone therapy. The goal is to see if YL201 can shrink tumors or slow the cancer's growth.
Hefei, AnhuiAges 18 years+ - NCT05464082RecruitingPhase 2
Collect tumor samples to guide early breast cancer recurrence care
This Phase 2 study tests a “precision” approach using tumor sample testing to help predict, prevent, and treat early metastatic recurrence in triple-negative or hormone-receptor–low, HER2-negative breast cancer. If you qualify, you’ll be asked to provide tumor tissue before (or in place of) standard chemotherapy, so researchers can learn which tumor features matter most.
Salt Lake City, UtahAges 18 years+ - NCT06492122RecruitingPhase 1
Study of a radioactive drug for advanced prostate cancer
This trial tests a new radioactive treatment, [225Ac]Ac-FL-020, for men with metastatic castration-resistant prostate cancer (mCRPC) that has gotten worse despite other treatments. It's for those who have had at least one prior hormone therapy or chemotherapy.
Duarte, CaliforniaAges 18 years+ - NCT07100704RecruitingPhase 2
Nivolumab for recurrent olfactory neuroblastoma
This trial tests the drug nivolumab for people with a rare nasal tumor (olfactory neuroblastoma) that has come back or spread and cannot be treated with surgery or radiation. You must have already tried chemotherapy and it stopped working. The goal is to see if nivolumab can shrink the tumor or slow its growth.
Kashiwa, ChibaAges 18 years+ - NCT05768503RecruitingPhase 3
Test new drugs after colorectal cancer chemotherapy
This Phase 3 trial compares a new treatment combination (chidamide plus sintilimab plus bevacizumab) versus the standard second-line chemotherapy (FOLFIRI plus bevacizumab) for advanced colorectal cancer that is microsatellite stable/low. It aims to see which treatment works better and is safer for people whose cancer grew after first-line oxaliplatin-based therapy.
Hefei, AnhuiAges 18–75 - NCT06897644RecruitingPhase 3
Comparing two chemotherapy strategies for advanced pancreatic cancer
This study compares two chemotherapy strategies for people with advanced pancreatic cancer who have not yet had treatment. The goal is to see if switching to a different chemotherapy combination (gemcitabine plus nab-paclitaxel) after initial treatment works better than staying on the original chemotherapy (modified FOLFIRINOX).
Aviano, ItalyAges 18 years+ - NCT06026657RecruitingPhase 1/Phase 2
NK cells with or without naxitamab for GD2-positive breast cancer
This trial tests a new treatment using immune cells called NK cells combined with chemotherapy (gemcitabine) and possibly naxitamab for people with a certain type of advanced breast cancer that has spread. It aims to see if this approach can help when standard treatments have stopped working.
Columbus, OhioAges 18 years+
Hear when a new Liver Cancer (Primary and Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver cancer (primary and metastatic)?
- Yes. Clin2 currently lists 319 recruiting liver cancer (primary and metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver cancer (primary and metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver cancer (primary and metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.